X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7985) 7985
Publication (818) 818
Book Review (57) 57
Book Chapter (17) 17
Dissertation (6) 6
Conference Proceeding (5) 5
Magazine Article (5) 5
Newsletter (5) 5
Streaming Video (3) 3
Data Set (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7167) 7167
male (4276) 4276
female (4066) 4066
index medicus (3644) 3644
adult (3330) 3330
sputum - microbiology (3282) 3282
middle aged (2964) 2964
sputum (2723) 2723
respiratory system (2148) 2148
aged (1863) 1863
tuberculosis (1563) 1563
adolescent (1430) 1430
infectious diseases (1365) 1365
asthma (1317) 1317
microbiology (1086) 1086
mycobacterium tuberculosis - drug effects (1062) 1062
immunology (1026) 1026
inflammation (1017) 1017
treatment outcome (990) 990
diagnosis (957) 957
mycobacterium tuberculosis - isolation & purification (943) 943
microbial sensitivity tests (869) 869
tuberculosis, pulmonary - drug therapy (855) 855
young adult (835) 835
child (825) 825
research article (809) 809
asthma - drug therapy (779) 779
antitubercular agents - therapeutic use (768) 768
induced sputum (763) 763
research (763) 763
cystic fibrosis (734) 734
pulmonary tuberculosis (703) 703
patients (699) 699
care and treatment (695) 695
sputum - cytology (691) 691
tuberculosis, pulmonary - microbiology (691) 691
medicine (672) 672
risk factors (657) 657
airway inflammation (656) 656
analysis (631) 631
infections (629) 629
anti-bacterial agents - therapeutic use (613) 613
health aspects (605) 605
tuberculosis, pulmonary - diagnosis (591) 591
administration, inhalation (588) 588
time factors (579) 579
drug resistance (572) 572
pharmacology & pharmacy (565) 565
allergy (557) 557
sputum - drug effects (550) 550
antibiotics (542) 542
double-blind method (538) 538
multidisciplinary sciences (522) 522
respiratory tract diseases (517) 517
drug therapy (513) 513
animals (510) 510
sputum - metabolism (508) 508
mycobacterium-tuberculosis (505) 505
aged, 80 and over (503) 503
retrospective studies (496) 496
anti-bacterial agents - pharmacology (485) 485
prospective studies (485) 485
disease (482) 482
infection (481) 481
obstructive pulmonary-disease (481) 481
medicine, general & internal (462) 462
studies (459) 459
children (454) 454
science (451) 451
asthma - physiopathology (446) 446
chronic obstructive pulmonary disease (443) 443
sensitivity and specificity (440) 440
antitubercular agents - pharmacology (439) 439
prevalence (438) 438
drug resistance, microbial (433) 433
epidemiology (424) 424
mortality (421) 421
sputum - chemistry (407) 407
mycobacterium tuberculosis - genetics (399) 399
chronic disease (395) 395
mycobacterium tuberculosis (395) 395
drug therapy, combination (390) 390
child, preschool (389) 389
lung diseases (385) 385
cystic fibrosis - microbiology (377) 377
copd (372) 372
bacteria (370) 370
respiratory function tests (370) 370
asthma - immunology (369) 369
biomarkers (358) 358
critical care medicine (358) 358
tuberculosis, multidrug-resistant - drug therapy (354) 354
medical research (352) 352
therapy (348) 348
hiv (346) 346
eosinophils (340) 340
pulmonary/respiratory (334) 334
cystic fibrosis - complications (329) 329
forced expiratory volume (328) 328
severity of illness index (326) 326
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7453) 7453
Japanese (144) 144
German (134) 134
Russian (125) 125
Chinese (65) 65
French (59) 59
Polish (47) 47
Italian (32) 32
Spanish (22) 22
Romanian (16) 16
Czech (5) 5
Danish (5) 5
Dutch (4) 4
Portuguese (4) 4
Turkish (4) 4
Croatian (3) 3
Korean (2) 2
Swedish (2) 2
Ukrainian (2) 2
Hungarian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 08/2015, Volume 10, Issue 8, pp. e0136861 - e0136861
Journal Article
European Respiratory Journal, ISSN 0903-1936, 10/2017, Volume 50, Issue 4, pp. 1700451 - 1700451
Inhaled corticosteroid-containing medications reduce the frequency of COPD exacerbations (mainly infectious in origin) while paradoxically increasing the risk... 
MORTALITY | OBSTRUCTIVE PULMONARY-DISEASE | FLUTICASONE PROPIONATE | BLOOD EOSINOPHILS | RESPIRATORY SYSTEM | EXACERBATIONS | INNATE | RISK | PNEUMONIA | PROTEINS | EXPRESSION | Sputum - microbiology | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Pulmonary Disease, Chronic Obstructive - microbiology | Humans | Middle Aged | Male | Drug Monitoring - methods | Salmeterol Xinafoate - adverse effects | Bacterial Load - drug effects | Forced Expiratory Volume | Respiratory Tract Infections - microbiology | Long Term Adverse Effects - microbiology | Pulmonary Disease, Chronic Obstructive - blood | Bacterial Load - methods | Female | Eosinophils - pathology | Bronchodilator Agents - adverse effects | Fluticasone - adverse effects | Glucocorticoids - adverse effects | Pulmonary Disease, Chronic Obstructive - diagnosis | Administration, Inhalation | Treatment Outcome | Salmeterol Xinafoate - administration & dosage | Respiratory Tract Infections - diagnosis | Long Term Adverse Effects - diagnosis | Fluticasone - administration & dosage | Respiratory Function Tests | Viral Load - drug effects | Viral Load - methods | Pulmonary Disease, Chronic Obstructive - drug therapy | Respiratory therapy | Corticoids | Leukocytes (eosinophilic) | Propionic acid | Salmeterol | Microbiomes | Inflammation | Fluticasone | Inhalation | Respiratory tract | Sputum | Bacteria | Chronic obstructive pulmonary disease | Long-term effects
Journal Article
Annals of internal medicine, ISSN 0003-4819, 2009, Volume 151, Issue 8, pp. 517 - 527
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2009, Volume 124, Issue 5, pp. 913 - 920.e7
Background Epidermal growth factor receptor ligands, such as epidermal growth factor (EGF) and amphiregulin, may play key roles in tissue remodeling in asthma.... 
Allergy and Immunology | bronchial asthma | tissue remodeling | bronchial epithelial cells | Amphiregulin | epidermal growth factor | TYROSINE PHOSPHORYLATION | LEUKOTRIENES | PROLIFERATION | IMMUNOLOGY | FACTOR RECEPTOR | BREAST-CANCER CELLS | REPAIR | EPITHELIAL-CELLS | ALLERGY | GENE-EXPRESSION | MUCIN PRODUCTION | GOBLET CELL | Intercellular Signaling Peptides and Proteins - analysis | Phosphorylation - physiology | Asthma - metabolism | Epithelial Cells - metabolism | Extracellular Signal-Regulated MAP Kinases - drug effects | Respiratory Mucosa - drug effects | Epithelial Cells - drug effects | Humans | Glycoproteins - metabolism | Child, Preschool | Infant | Male | Extracellular Signal-Regulated MAP Kinases - metabolism | Glycoproteins - pharmacology | Epidermal Growth Factor - analysis | Respiratory Mucosa - pathology | Intercellular Signaling Peptides and Proteins - metabolism | EGF Family of Proteins | Female | Proto-Oncogene Proteins c-fos - agonists | Phosphorylation - drug effects | Myocytes, Smooth Muscle - drug effects | Child | Myocytes, Smooth Muscle - metabolism | Infant, Newborn | Fibroblasts - metabolism | Mucin 5AC - agonists | Cell Line | Acute Disease | Cells, Cultured | Proto-Oncogene Proteins c-fos - metabolism | Epidermal Growth Factor - metabolism | Epithelial Cells - pathology | Recombinant Proteins - pharmacology | Sputum - chemistry | Signal Transduction - drug effects | Intercellular Signaling Peptides and Proteins - pharmacology | Fibroblasts - drug effects | Adolescent | Mucin 5AC - metabolism | Signal Transduction - physiology | Cell Proliferation - drug effects | Epidermal Growth Factor - pharmacology | Glycoproteins - analysis | Respiratory Mucosa - metabolism | Asthma - pathology | Medical colleges | Enzymes | Epidermal growth factor | Mucins | Children | Health aspects | Asthma | Ligands | Smooth muscle | Airway management | Hospitalization
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD009764
Background There has been renewal of interest in the use of prophylactic antibiotics to reduce the frequency of exacerbations and improve quality of life in... 
Fluoroquinolones | Quinolines | Clarithromycin | Lungs & airways | Drug Administration Schedule | Pulmonary Disease, Chronic Obstructive | Azithromycin | Antibiotic Prophylaxis | Roxithromycin | Erythromycin | Moxifloxacin | Disease Progression | Randomized Controlled Trials as Topic | Trimethoprim, Sulfamethoxazole Drug Combination | Chronic obstructive pulmonary disease (stable) | Amoxicillin | Anti‐Bacterial Agents | Aza Compounds | Clavulanic Acid | Quality of Life | Chronic obstructive pulmonary disease, stable ‐ pharmacotherapy | Medicine General & Introductory Medical Sciences | Other medications | Azithromycin [therapeutic use] | STABLE COPD | Humans | AIRWAY INFLAMMATION | Quinolines [therapeutic use] | Anti-Bacterial Agents [therapeutic use] | MEDICINE, GENERAL & INTERNAL | DAILY PENICILLIN | Aza Compounds [therapeutic use] | TETRACYCLINE | Erythromycin [therapeutic use] | CHRONIC-BRONCHITIS | LONG-TERM AZITHROMYCIN | Antibiotic Prophylaxis [methods] | Pulmonary Disease, Chronic Obstructive [drug therapy] | ACUTE EXACERBATIONS | INDUCED SPUTUM | Clarithromycin [therapeutic use] | DOUBLE-BLIND | Aged | HEALTH-STATUS | Aza Compounds - therapeutic use | Anti-Bacterial Agents - therapeutic use | Anti-Bacterial Agents - adverse effects | Roxithromycin - adverse effects | Roxithromycin - therapeutic use | Antibiotic Prophylaxis - methods | Clarithromycin - therapeutic use | Trimethoprim, Sulfamethoxazole Drug Combination - adverse effects | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Erythromycin - therapeutic use | Clavulanic Acid - adverse effects | Clavulanic Acid - therapeutic use | Azithromycin - adverse effects | Moxifloxacin - therapeutic use | Azithromycin - therapeutic use | Amoxicillin - therapeutic use | Amoxicillin - adverse effects | Quinolines - therapeutic use | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2017, Volume 2020, Issue 3, p. CD009528
Background The antibiotics used to treat pulmonary infections in people with cystic fibrosis are typically chosen based on the results of antimicrobial... 
Genetic disorders | Lungs & airways | Cystic Fibrosis | Cystic fibrosis: antibiotics | TREATMENT | Respiratory Tract Infections | Randomized Controlled Trials as Topic | Microbial Sensitivity Tests | Biofilms | Antibiotics | Anti‐Bacterial Agents | Sputum | Child health | Fibrosis: cystic fibrosis | Pseudomonas aeruginosa | Pseudomonas Infections | Medicine General & Introductory Medical Sciences | PULMONARY INFECTION | ACUTE THERAPY (PULMONARY EXACERBATIONS) | SURVIVAL | Pseudomonas Infections [ drug therapy] | REPEATED EXPOSURE | Humans | Cystic Fibrosis [complications] | METAANALYSES | Male | AZTREONAM | Anti-Bacterial Agents [therapeutic use] | MEDICINE, GENERAL & INTERNAL | PSEUDOMONAS-AERUGINOSA | Adult | Female | Biofilms [drug effects; growth & development] | Respiratory Tract Infections [drug therapy; microbiology] | PULMONARY EXACERBATIONS | COLONIZATION | CHILDREN | Pseudomonas aeruginosa [ drug effects; physiology] | Microbial Sensitivity Tests [methods] | Adolescent | DISEASE | INHALATION SOLUTION AZLI | Sputum [microbiology] | Biofilms - drug effects | Sputum - microbiology | Pseudomonas Infections - drug therapy | Biofilms - growth & development | Respiratory Tract Infections - drug therapy | Pseudomonas aeruginosa - physiology | Pseudomonas aeruginosa - drug effects | Cystic Fibrosis - complications | Respiratory Tract Infections - microbiology | Anti-Bacterial Agents - therapeutic use | Microbial Sensitivity Tests - methods
Journal Article
Journal Article
Respirology, ISSN 1323-7799, 01/2005, Volume 10, Issue 1, pp. 46 - 56
Journal Article
The Lancet, ISSN 0140-6736, 02/2004, Volume 363, Issue 9409, pp. 600 - 607
Lower respiratory tract infections are often treated with antibiotics without evidence of clinically relevant bacterial disease. Serum calcitonin precursor... 
DIAGNOSIS | ETIOLOGY | MEDICINE, GENERAL & INTERNAL | COMMUNITY-ACQUIRED PNEUMONIA | OBSTRUCTIVE PULMONARY-DISEASE | IMPACT | MANAGEMENT | THERAPY | EXACERBATIONS | SEPSIS | ACUTE BRONCHITIS | Calcitonin Gene-Related Peptide | Single-Blind Method | Acute Disease | Calcitonin - blood | Bronchitis - blood | Protein Precursors - blood | Bacterial Infections - drug therapy | Humans | Middle Aged | Male | Respiratory Tract Infections - drug therapy | Treatment Outcome | Drug Utilization Review | Respiratory Tract Infections - microbiology | Anti-Bacterial Agents - therapeutic use | Pneumonia - drug therapy | Bronchitis - drug therapy | Pulmonary Disease, Chronic Obstructive - blood | Female | Pneumonia - blood | Aged | Bacterial Infections - blood | Respiratory Tract Infections - blood | Pulmonary Disease, Chronic Obstructive - drug therapy | Respiratory tract infections | Case studies | Lung diseases, Obstructive | Care and treatment | Health aspects | Calcitonin | Clinical trials | Antibiotics | Drug therapy | Respiratory diseases | Pneumonia | Intensive care | Laboratories | Procalcitonin | Infections | Emergency medical care | Family medical history | Drug resistance | Antiinfectives and antibacterials | Evidence-based medicine | Blood | Subgroups | Proteins | Respiratory tract | Dyspnea | Motivation | Quality | Bacteria | Respiratory tract diseases | Chronic obstructive pulmonary disease | Bronchitis | Bacterial infections | Lung diseases | Body temperature | Patients | Asthma | Hospitals | Obstructive lung disease | Sputum | Diagnostic systems | Viral infections
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2015, Volume 10, Issue 9, p. e0138340
Background Development of new tuberculosis (TB) drugs and alternative treatment strategies are urgently required to control the global spread of TB. Previous... 
MYCOBACTERIUM-TUBERCULOSIS | HUMAN MACROPHAGES | IMMUNE-RESPONSES | MULTIDISCIPLINARY SCIENCES | ANTIMICROBIAL PEPTIDE LL-37 | DOUBLE-BLIND | D DEFICIENCY | HOST-DIRECTED THERAPY | PLACEBO-CONTROLLED TRIAL | CATHELICIDIN LL-37 | CUTTING EDGE | Sputum - microbiology | Leukocytes, Mononuclear - metabolism | Tuberculosis, Pulmonary - microbiology | Phenylbutyrates - therapeutic use | Humans | Tuberculosis, Pulmonary - drug therapy | Antimicrobial Cationic Peptides - metabolism | RNA, Messenger - metabolism | Calcium - blood | Cholecalciferol - therapeutic use | Adult | Female | Antimicrobial Cationic Peptides - genetics | C-Reactive Protein - analysis | Drug Therapy, Combination | Macrophages - immunology | Antitubercular Agents - therapeutic use | Calcifediol - blood | Double-Blind Method | Administration, Oral | Placebo Effect | Logistic Models | Treatment Outcome | Macrophages - cytology | Tuberculosis, Pulmonary - pathology | Macrophages - metabolism | Chemotherapy | Tuberculosis | Peptides | Analysis | Clinical trials | Esters | Rankings | Research | Macrophages | Vitamins | Cancer | Cell culture | Vitamin D3 | Substance abuse treatment | Pandemics | Disease | Laboratories | Systematic review | Infections | Drug development | Drug resistance | Recovery | Randomization | Vitamin D | Human immunodeficiency virus--HIV | Smear | Drug dosages | Inducers | Vitamin deficiency | Gene expression | Patients | Shigellosis | Medicine | Monocytes | Hospitals | Microscopy | Sputum | Diabetes | Phenylbutyric acid | HIV | Human immunodeficiency virus
Journal Article